贝达药业：投资5000万元入股杭州知兴制药

Core Viewpoint - Beida Pharmaceutical has completed the equity transfer with Huayuan Group, acquiring a 20% stake in Hangzhou Zhixing Pharmaceutical for 50 million yuan, which will enhance its new drug development technology platform and expand its strategic layout in disease treatment [1] Group 1 - Beida Pharmaceutical invested 50 million yuan to acquire a 20% stake in Hangzhou Zhixing Pharmaceutical [1] - Zhixing Pharmaceutical focuses on the development of high-end inhalation formulations and has established a comprehensive R&D and production system [1] - The investment does not constitute a related party transaction or a major asset restructuring, and does not require approval from relevant authorities [1] Group 2 - This investment will help Beida Pharmaceutical to broaden its strategic layout in the field of disease treatment [1]